Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | HPGDS | O60760 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7175482 | 1.00 | KCNH2 (0.44) | KCNH2SCN9AHPGDSHRH3PRMT5 | |
| SCHEMBL6823150 | 0.91 | DRD2 (0.48) | KCNH2SCN9ADRD2HTR2ADRD3 | |
| SCHEMBL6816571 | 0.91 | DRD2 (0.48) | KCNH2SCN9ADRD2HTR2ADRD3 | |
| SCHEMBL7246436 | 0.88 | HPGDS (0.41) | KCNH2SCN9AHPGDSHRH3PRMT5 | |
| SCHEMBL7246432 | 0.88 | HPGDS (0.41) | KCNH2SCN9AHPGDSHRH3PRMT5 | |
| SCHEMBL6816677 | 0.88 | SMN1; SMN2 (0.42) | KCNH2SCN9AHPGDS | |
| SCHEMBL6820035 | 0.87 | MTNR1A (0.47) | KCNH2SCN9AHPGDSPRMT5DRD2 | |
| SCHEMBL6820059 | 0.87 | MTNR1A (0.47) | KCNH2SCN9AHPGDSPRMT5DRD2 | |
| SCHEMBL7024691 | 0.84 | KCNH2 (0.48) | KCNH2SCN9AHPGDSHRH3PRMT5 | |
| SCHEMBL7023935 | 0.84 | KCNH2 (0.48) | KCNH2SCN9AHPGDSHRH3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | claimed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | claimed |
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | claimed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | claimed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | claimed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159971-A | Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| EP-1021183-A1 | A COMBINATION OF A SELECTIVE 5-HT 1A? ANTAGONIST AND A SELECTIVE h5-HT 1B? ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-26 | — | — | EP | disclosed |
| EP-1014986-A1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-05 | — | — | EP | disclosed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999013878-A1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013876-A1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | KCNH2 2034/4885SCN9A 635/4885HPGDS 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.